If you are a mid-career professional in pharmaceuticals, this is a good week for your resume. Hiring requests from India’s pharma and life sciences sector rose 20 per cent between April and September 2026, according to a report by Spectrum Talent Management released on October 17. The number that should catch every jobseeker’s eye: six out of ten of those hiring requests were for mid-career talent, professionals with four to eight years of experience.
It is a sharp signal about where the industry’s hiring engine is moving. Indian pharma has spent years scaling up plants and capacity. Now the hiring story is about skills that are harder to find: people who can clear a regulatory audit, build an AI model for drug discovery, or steer a complex generics programme from lab to market.
Where the demand is coming from
The report lists the roles that drove most of the 20 per cent jump. Regulatory affairs led the pack, followed by data analytics and AI/ML, operational excellence, complex generic R&D, supply chain, and global capability centres, or GCCs.
The pattern makes sense when you look at what pharma companies are actually doing right now. Large manufacturers and GCCs are pouring money into digital drug discovery, AI-led clinical research and advanced analytics. That push needs data scientists and AI talent who understand biology, a combination that remains rare. Meanwhile, the move into biosimilars, biologics and complex generics demands specialised R&D professionals who simply do not grow on trees.
Then there is the regulatory angle. Scrutiny from the US FDA, European agencies and domestic regulators has turned regulatory affairs and quality assurance into senior-level priority hires. Companies would rather pay for experience than pay for a failed inspection later.
From capacity to capability
“Pharma and life sciences are moving from adding capacity to adding capability,” said Atanu Banerjee, Chief Executive Officer at Spectrum Talent Management. “Companies are increasingly using contract and flexible talent to meet these needs, while continuing to hire permanently for core roles.”
That second line matters. Not every opening is a permanent job on the rolls. Employers are leaning on contract and flexible professionals for project-heavy work like regulatory submissions or analytics builds, while keeping permanent hiring for the roles they consider core. For experienced professionals, it means two viable paths into
the sector: the traditional full-time route and a growing pool of high-value contract assignments.
The policy tailwind behind the numbers
The hiring surge is riding a strong policy push. The report notes that the government’s pharma production-linked incentive, or PLI, scheme has attracted Rs 46,744 crore in investments and created over 1.21 lakh jobs as of June 2026. The bulk drugs scheme, aimed at cutting India’s dependence on imported ingredients, has commissioned 39 projects across 28 active pharmaceutical ingredients and key starting materials.
Those numbers matter for careers because every new PLI-linked plant or bulk drug facility eventually needs people: production chemists, quality control analysts, supply chain managers and regulatory staff. The incentive money being sanctioned this year becomes the job openings of next year.
What this means for your career
- Mid-career is the sweet spot: With 60 per cent of demand sitting in the 4 to 8 year experience band, professionals who once feared being too experienced to switch are actually the most sought after.
- Regulatory and quality skills pay: Regulatory affairs, quality assurance and compliance professionals are being hired at senior levels. A record of clean audits is a genuine differentiator.
- Data and AI open a side door: Data analytics and AI/ML are among the fastest-growing drivers. Pharma experience plus a data toolkit is a rare and valuable mix.
- GCCs are hiring quietly: Global capability centres of multinational pharma firms are expanding in India and recruiting across research, analytics and support functions.
- Contract roles are real work: Flexible and contract assignments are being used for serious, high-skill projects, not just stopgap roles. They can be a way in.
Frequently Asked Questions
What does the Spectrum Talent Management report say about pharma hiring?
Hiring requests from India’s pharma and life sciences sector rose 20 per cent in April-September 2026 compared with the previous period, with mid-career professionals driving most of the demand.
Which roles are in highest demand in pharma right now?
Regulatory affairs, data analytics, AI and machine learning, operational excellence, complex generic R&D, supply chain and GCC roles are the key hiring drivers, according to the report.
How much experience do pharma companies want?
Professionals with 4 to 8 years of experience accounted for 60 per cent of hiring demand, making mid-career talent the most sought-after segment.
Is hiring limited to permanent jobs?
No. Companies are using contract and flexible talent for specialised needs while continuing to hire permanently for core roles, so both routes are open.
What is driving the hiring boom in Indian pharma?
Digital drug discovery, AI-led clinical research, the push into biosimilars and complex generics, tighter regulatory scrutiny, and government schemes like the pharma PLI, which has drawn Rs 46,744 crore in investment and created over 1.21 lakh jobs as of June 2026.
The takeaway is simple: Indian pharma is not just hiring more people, it is hiring different people. If your skills match where the industry is headed, from regulatory expertise to data fluency, the next few months could be the busiest your inbox has been in years.
